Try Then Buy? Sutro Deal Could Be Celgene’s Biggest Antibody Bet Yet

Posted: October 23rd, 2014  |  Company/topic: Celgene
Website:
Alex Lash Celgene, one of biopharma’s most aggressive and creative dealmakers, said Thursday it has forged a deep partnership with South San Francisco, CA-based Sutro Biopharma that could end…

Celgene profits leap on multiple myeloma drugs

Posted: October 23rd, 2014  |  Company/topic: Celgene
Website:
Celgene profits leap on multiple myeloma drugs…

Celgene’s powerhouse Revlimid gets a little Q3 help from new friends Pomalyst, Otezla

Posted: October 23rd, 2014  |  Company/topic: Celgene
Website:
Celgene's growth engine Revlimid came through again this quarter. The blood cancer drug's $1.3 billion in Q3 sales--a 19% increase--helped the company hit sales estimates and beat profit expectations.

Celgene adds $1B-plus immuno-oncology deal, buyout option for Sutro

Posted: October 23rd, 2014  |  Company/topic: Celgene
Website:
Close to two years after Celgene closed its first development deal with Sutro Biopharma, the prolific partnering machine at the big biotech has come back and taken an option on buying the company and…